clinical trial · NCT07633314
A Clinical Trial Comparing TQC3927 Inhaled Powder With Glycopyrronium Bromide and Formoterol Inhaled Aerosol (Biovoping® Lingchang®) for the Treatment of Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·phase2·not yet recruiting·n = 90
Chronic Obstructive Pulmonary DiseaseTQC3927 inhalation aerosolGlyceryl bromide/formoterol inhalation aerosol
brief summary
This is a multicenter, randomized, open-label, positive-drug controlled study designed to evaluate the preliminary efficacy and safety of different doses of TQC3927 inhaled powder for short-term treatment of patients with chronic obstructive pulmonary disease, and to observe the symptoms and pharmacokinetic (PK) characteristics of participants.
started
Jul 1, 2026
primary completion
Dec 1, 2026
completion
Jan 1, 2027
last updated
Jun 8, 2026
official title
A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Trial to Explore the Efficacy and Safety of Different Doses of TQC3927 Inhaled Powder in Patients With Chronic Obstructive Pulmonary Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol